Johnson & Johnson приобретает Ollin Biosciences за $3,3 млрд

Stock Market News

16 ноября 2026, 18:43

В понедельник Johnson & Johnson (NYSE: KNK) объявила о приобретении биофармацевтической компании Ollin Biosciences Inc. Сумма сделки включает первоначальный платеж в размере $2,2 млрд, а также дополнительные выплаты в размере до $1,1 млрд, привязанные к достижению определенных этапов разработки препаратов. Это приобретение позволит Johnson & Johnson расширить портфель лекарств для лечения заболеваний глаз, поскольку Ollin Biosciences занимается разработкой антитела для терапии сосудистых заболеваний сетчатки. Ожидается, что сделка будет закрыта до конца 2026 г. В Johnson & Johnson также сообщили о заключении соглашения с инвестиционной компанией Blackstone, которая профинансирует проведение третьей фазы клинических исследований данного антитела. Взамен Blackstone получит право на выплаты при достижении регуляторных и коммерческих целей, а также на получение роялти в размере нескольких процентов от объема продаж.

16, Dostyk street, integral non-residential facility No.2, Yessil district Astana, Republic of Kazakhstan (Talan Towers Offices).

+7 7172 67 77 55 - Free from landline numbers in Kazakhstan; calls from international and mobile numbers are chargeable.

(+7 727 3557555 – additional)

7555 - free from mobile operators in Kazakhstan [email protected], [email protected]

Notify about fraudulent activities or security issues regarding this resource: fbroker.kz/trustcenter

Owning securities and other financial instruments is always associated with risks: the value of securities and other financial instruments can both rise and fall. Past investment results do not guarantee future income. In accordance with the law, the company does not guarantee or promise future returns on investments, nor does it provide guarantees regarding the reliability of potential investments or the stability of potential income.

Freedom Finance Global PLC provides brokerage (agency) services in the securities market on the territory of the Astana International Financial Center (hereinafter referred to as AFSA) in the Republic of Kazakhstan. Subject to compliance with requirements, conditions, restrictions and/or directions of the Acting Law of the AFSA, the Company is authorized to conduct the following Regulated Activities under License No. AFSA-A-LA-2020-0019: Dealing in Investments as Principal, Dealing in Investments as Agent, Managing Investments, Advising on Investments, Arranging Deals in Investments.

S&P Global ratings – “BB-”, outlook “Positive”.

Ownership of securities and other financial instruments always involves risks: the cost of securities and other financial instruments may rise or fall. Past investment results do not guarantee future returns. In accordance with the legislation, the company does not guarantee or promise the profitability of investments in the future, does not guarantee the reliability of possible investments and the stability of the amount of possible income.

The information on the website is updated as part of keeping the data up-to-date and meeting regulatory disclosure requirements. Please note that these updates are for informational purposes only and are not marketing materials!